Lilly ordered to pay $3 billion for hiding cancer risk of drug
Takeda Pharmaceutical Co. and Eli Lilly and Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind. Lilly's portion of the damage award is $3 billion, an amount that represents nearly 13 percent of its 2013 revenue total of $23.1 billion. IBJ has the story.